These documents provide a comprehensive overview of Waters Corporation's financial performance for the first quarter of 2026, highlighted by the successful integration of newly acquired biosciences and diagnostic businesses. The company reported total revenue of $1.267 billion, surpassing expectations due to strong commercial execution and growth in its analytical sciences and organic divisions. While GAAP earnings showed a loss due to one-time acquisition costs, the adjusted earnings per share rose to $2.70, reflecting a 20% year-over-year increase. Management expressed confidence in future synergy by raising full-year guidance for organic revenue and profitability. Detailed financial tables and balance sheets are included to reconcile standard accounting with adjusted metrics for investors. Overall, the sources depict a company transitioning into a powerful new era of growth through strategic expansion and high-tech laboratory innovation.